CASSAVA SCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
Get Help
Cassava investors should visit us at or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
About the Lawsuit
Cassava and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On November 25, 2024, the Company disclosed topline results for the first of its two ongoing Phase 3 studies on its leading drug candidate, simufilam, the“ReThink-ALZ” study, that indicated that simufilam failed to meet each of the pre-specified primary, secondary, and exploratory endpoints; in sum, simufilam failed to outperform the placebo.
On this news, the price of Cassava's shares fell approximately 83%, from a closing price of $26.48 per share on November 22, 2024, to $4.30 per share on November 25, 2024.
The case is Crocker v. Cassava Sciences, Inc., et al., No. 24-cv-1525.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit .

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment